26.06.2023 15:13:56
|
Vertex Pharma, Lonza Collaborate To Build Manufacturing Facility For Type 1 Diabetes Cell Therapies
(RTTNews) - Vertex Pharmaceuticals Inc (VRTX) and Lonza (LONN.SW) have announced a strategic collaboration aimed at supporting the manufacturing of Vertex's portfolio of investigational stem cell-derived islet cell therapies for individuals with Type 1 diabetes or T1D.
The collaboration will specifically focus on VX-880 and VX-264 programs, which are currently undergoing clinical trials.
-- VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, is under a phase I/II trial in Type 1 diabetes. According to new data reported last week, all six patients in the trial treated with VX-880, produced endogenous insulin and had improved glycemic control while reducing or eliminating insulin use.
-- VX-264, a fully differentiated cells encapsulated in immunoprotective device, is also under a phase I/II trial in Type 1 diabetes.
Vertex's Type 1 diabetes portfolio also includes hypoimmune cell therapies, currently in preclinical development.
As part of the collaboration, Vertex and Lonza will join forces to build a dedicated new facility in Portsmouth, New Hampshire, that will support the commercial production of Vertex's T1D cell therapy portfolio. The construction of this manufacturing facility is set to commence later this year.
VRTX closed Friday's trading at $347, down 0.33%. In premarket trading, Monday, the stock is up over 1% at $350.52
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Vertex Pharmaceuticals Inc.mehr Nachrichten
31.01.25 |
Schwacher Handel in New York: NASDAQ Composite schließt in der Verlustzone (finanzen.at) | |
31.01.25 |
Börse New York in Rot: S&P 500 notiert letztendlich im Minus (finanzen.at) | |
31.01.25 |
Börse New York in Grün: S&P 500 verbucht am Freitagnachmittag Gewinne (finanzen.at) | |
31.01.25 |
Pluszeichen in New York: Pluszeichen im NASDAQ 100 (finanzen.at) | |
31.01.25 |
Pluszeichen in New York: NASDAQ Composite-Börsianer greifen am Freitagnachmittag zu (finanzen.at) | |
31.01.25 |
NASDAQ Composite-Handel aktuell: NASDAQ Composite-Anleger greifen zu (finanzen.at) | |
31.01.25 |
NASDAQ 100-Handel aktuell: NASDAQ 100 legt am Mittag zu (finanzen.at) | |
31.01.25 |
Börse New York in Grün: S&P 500 mit positivem Vorzeichen (finanzen.at) |
Analysen zu Vertex Pharmaceuticals Inc.mehr Analysen
Aktien in diesem Artikel
Vertex Pharmaceuticals Inc. | 444,40 | 5,26% |